๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

E17K substitution in AKT1 in prostate cancer

โœ Scribed by Boormans, J L; Korsten, H; Ziel-van der Made, A C J; van Leenders, G J L H; Verhagen, P C M S; Trapman, J

Book ID
110000467
Publisher
Nature Publishing Group
Year
2010
Tongue
English
Weight
179 KB
Volume
102
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

AKT1E17K in human solid tumours
AKT1E17K in human solid tumours
โœ Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Bleeker, F E; Felicioni, L; ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 106 KB
An activating mutation in AKT1 in human
An activating mutation in AKT1 in human prostate cancer
โœ Joost L. Boormans; Karin G. Hermans; Geert J.L.H. van Leenders; Jan Trapman; Pau ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 688 KB

The phosphatidylinositol 3-kinase (PI3K) AKT pathway is frequently activated in human cancers. 1 PI3K catalyzes the synthesis of phosphorylated phosphoinositides, resulting in AKT1 activation. PI3K is counteracted by the phosphatase PTEN, which is often inactivated in prostate cancer. In prostate ca